Immunologic pathways in a quantitative model of immunosuppression based on rejection of an allogeneic or xenogeneic tumor graft

Transplantation

Volumn 79, Issue 8, 2005, Pages 889-896

  Hammond McKibben, Denise ^a   Saulnier, Muriel ^b   Zhang, Jin ^b   Risher, Nicole ^c   Lake, Philip ^b   Weetall, Marla ^c  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PTC THERAPEUTICS   (United States)

Author keywords

Allogeneic tumor rejection; High capacity animal model; Second set rejections; Synergy

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; OKT 8; PERFORIN;

ALLOGRAFT; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; HISTOCOMPATIBILITY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; SPLEEN CELL; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR REJECTION; TUMOR VOLUME; XENOGRAFT;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; MEMBRANE GLYCOPROTEINS; MICE; MODELS, IMMUNOLOGICAL; NEOPLASM TRANSPLANTATION; PORE FORMING CYTOTOXIC PROTEINS; SARCOMA; SPLEEN; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 17844371369     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000157361.50830.22     Document Type: Article

References (45)

1. Mitchison NA. Studies in the immunological response to foreign tumor transplants in the mouse. J Exp Med 1955; 102: 157.
2. McKibben D, Zhang J, Hugo R, et al. A high-capacity quantitative mouse model of drug-mediated immunosuppression based on rejection of an allogeneic subcutaneous tumor. J Pharmacol Exp Therapeut 2001; 297: 1144.
3. Smith DM, Fitch FW. Cellular stimuli for rejection of sarcoma tumor allografts by Balb/C recipient mice. Cell Immunol 1989; 118: 358.
4. Cole GA, Ostrand-Rosenberg S. Rejection of allogeneic tumor is not determined by host response to MHC Class I molecules and is mediated by CD4-CD8+ T lymphocytes that are not lytic for the tumor. Cell Immunol 1991; 135: 480.
5. Smith D, Stuart FP, Wemhoff GA, et al. Cellular pathways for rejection of Class I MHC-disparate skin and tumor allografts. Transplantation 1988; 45: 168.
6. Lamouse-Smith E, Clements VK, Ostrand-Rosenberg S. β2M -/-knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection. J Immunol 1993; 151: 6283.
7. Mullbacher A, Flynn K. Aspects of cytotoxic T cell memory. Immunol Rev 1996; 150: 113.
8. Bingaman AW, Farber DL. Memory T cells in transplantation: generation, function, and potential role in rejection. Am J Transplant 2004; 4: 846.
9. Kupiec-Weglinski JW. Graft rejection in sensitized recipients. Ann Transplant 1996; 1: 34.
10. Cascalho M, Platt JL. The immunological barrier to xenotransplantation. Immunity 2001; 14: 437.
11. Mandel TE, Kovarik J, Koulmanda M, et al. Cellular rejection of fetal pancreas grafts: differences between allo- and xenograft rejection. Xenotransplantation 1997; 4: 2.
12. Mombaerts P, Clarke AR, Rudnicki MA, et al. Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature 1992; 360: 231.
13. Itohara S, Mombaerts P, Lafaille J, et al. T cell receptor delta gene mutant mice: independent generation of alpha beta T cells and programmed rearrangements of gamma delta TCR genes. Cell 1993; 72: 337.
14. Walsh CM, Matloubian M, Liu CC, et al. Immune function in mice lacking the perform gene. Proc Natl Acad Sci U S A 1994; 91: 10854.
15. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16: 39.
16. King PD, Sandberg ET, Selvakumar A, et al. Novel isoforms of murine intracellular adhesion molecule-1 generated by alternative RNA splicing. J Immunol 1995; 154: 6080.
17. Grusby MJ, Hohnson RS, Papaioannou VE, et al. Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice. Science 1991; 253: 1417.
18. + cytolytic T cells. Nature 1990; 344: 742.
19. Dialynas DP, Wilde DB, Marrack P, et al. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev 1983; 74: 29.
20. Sriram S, Carroll L. In vivo depletion of Lyt-2 cells fails to alter acute and relapsing EAE. J Neuroimmunol 1988; 17: 147.
21. Miyake K, Weisaman IL, Greenberger JS, et al. Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J Exp Med 1991; 173: 599.
22. Leo O, Foo M, Sachs DH, et al. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci U S A 1987; 84: 1374.
23. Vremec D, Shortman K. Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J Immunol 1997; 159: 565.
24. Kern F, Docke WD, Reinke P, et al. Discordant expression of LFA-1, VLA-4alpha, VLA-beta 1, CD45RO and CD28 on T-cell subsets: evidence for multiple subsets of "memory" T cells. Int Arch Allergy Immunol 1994; 104: 17.
25. Isobe M, Hori J, Suzuki J. Immunosuppression by blocking alpha 4-integrins/VCAM-1 adhesion. Curr Top Microbiol Immunol 1998; 231: 85.
26. Coelho V, Moliterno R, Higuchi ML, et al. Gamma delta T cells play no major role in human heart allograft rejection. Transplantation 1995; 60: 980.
27. Gorczynski RM, Chen Z, Fu XM, et al. Gamma delta TCR+ cells regulate rejection of small intestinal allografts in rats. Transplant Proc 1997; 29: 863.
28. Tomita Y, Mayumi H, Eto M, et al. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens. J Immunol 1990; 144: 2425.
29. Mieno M, Suto R, Obata Y, et al. CD4-CD8- T cell receptor T cells: generation of an in vitro MHC-I specific CTL response and allogeneic tumor rejection. J Exp Med 1991; 174: 193.
30. Loveland BE, McKenzie IF. Cells mediating graft rejection in the mouse. II. The Ly phenotypes of cells producing tumor allograft rejection. Transplantation 1982; 33: 174.
31. Koeppen H, Acena M, Drolet A, et al. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes. Eur J Immunol 1993; 23: 2770.
32. Michaelides M, Hogarth PM, McKenzie IF. The immunosuppressive effect of monoclonal anti-Lyt-1.1. antibodies in vivo. Eur J Immunol 1981; 11: 1005.
33. 2+ dependent, Fas- and perforin-independent apoptotic death of allografted tumor cells by a type of activated macrophage. J Immunol 1997; 159: 15.
34. Schultz M, Schuurman HJ, Joergensen J, et al. Acute rejection of vascular heart allografts by perforin-deficient mice. Eur J Immunol 1995; 25: 474.
35. Ahmed KR, Guo TB, Gaal KK. Islet rejection in perforin-deficient mice: the role of perform and Fas. Transplantation 1997; 63: 951.
36. Baker MB, Podack ER, Levy RB. Perforin-and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Biol Blood Marrow Transplant 1995; 1: 69.
37. Tang ML, Hale LP, Steeber DA, et al. L-selectin is involved in lymphocyte migration to sites of inflammation in the skin: delayed rejection of allografts in L-selectin-deficient mice. J Immunol 1997; 158: 5191.
38. Schowengerdt KO, Zhu JY, Stepkowski SM, et al. Cardiac allograft survival in mice deficient in intercellular adhesion molecule-1. Circulation 1995; 92: 82.
39. Harrison PC, Mainolfi E, Madwed JB. Cyclosporine dosage can be reduced when used in combination with an anti-intercellular adhesion molecule-1 monoclonal antibody in rats undergoing heterotopic heart transplantation. J Heart Lung Transplant 1998; 17: 150.
40. Stepkowski SM, Wang ME, Condon TP, et al. Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides. Transplantation 1998; 66: 699.
41. Berenbaum M. What is synergy? Pharm Rev 1989; 41: 93.
42. Smyth MJ, Kershaw MH, Trapani JA. Xenospecific cytotoxic T lymphocytes: potent lysis in vitro and in vivo. Transplantation 1997; 63: 1171.
43. Smyth MJ, Kershaw MH, Darcy PK, et al. Adoptive transfer: the role of perforin in mouse cytotoxic T lymphocyte rejection of human tumor xenografts in vivo. Xenotransplantation 1998; 5: 146.
44. Pierson Winn HJ, Russell PS, Auchincloss H Jr. Xenogeneic skin graft rejection is especially dependent on CD4 T cells. J Exp Med 1989; 170: 991.
45. Uchida T, Tomita Y, Anzai K, et al. Roles of CD4+ and CD8+ T cells in discordant skin xenograft rejection. Transplantation 1999; 68: 1721.